It is illustrative to put the individual components of the global diabetes market into context. Below is illustrated the global diabetes market segmented by geography, with further detail shown for the U.S. markets product segments. The U.S. represents the single largest share of the global diabetes market, with insulin, glucose meter test strips (not including [...]
Type 1 diabetes is still treated with insulin injections. Insulin is supplied in a variety of long, intermediate and short-acting preparations. The duration of action of insulin preparations required to give optimal control varies from patient to patient. This means that individual patients are established on particular regimens which are not changed unless they are [...]
The market for tissue engineering and cell therapy products is set to grow to nearly $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment in the overall [...]
The U.S. market for products in the management of diabetes represents roughly 38% of a $41 billion global annual market. Products in the market are currently comprised of blood glucose monitors, lancets and test strips, continuous blood glucose monitors, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The most significant growth [...]
(See PRLog press release at link.) As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence. FOR IMMEDIATE RELEASE PRLog (Press Release) – Aug [...]
A diabetes epidemic is under way. According to the IDF (International Diabetes Federation) some 286 million people worldwide have diabetes. It is now one of the most common non- communicable diseases globally. Diabetes is the fourth or fifth leading cause of death in most developed countries and there is substantial evidence that it is epidemic [...]
This was the first large-scale study to show definitively the benefit of making efforts to keep blood glucose levels within tight limits. The results have had a significant effect on the directions of new diabetes management research. The Diabetes Control and Complications Trial (DCCT) was a 10-year study involving 1,441 people with insulin-dependent diabetes throughout [...]
The growing global prevalence of type 1 and 2 diabetes, driven by obesity and other forces, is creating strong clinical demand for a diverse set of diagnosis, monitoring and treatment products that are steadily evolving to better manage the disease. PRLog (Press Release) – Jul 20, 2010 – The diabetes market, which includes both pharmaceuticals and medical devices, [...]
Unlike type 1 diabetes, the initial management of the type 2 form of the disease is not dependent on insulin. Due to the different pathology of the type 2 diabetes, the management of this condition revolves around a strict regimen of exercise and diet (non-pharmacological means) and agents that aid insulin sensitivity (pharmacological methods). Another [...]
The diabetes market, which includes both pharmaceuticals and medical devices, is large and is growing steadily for four main reasons. First, the prevalence of diabetes is increasing, particularly that of type 2 in developed countries and those with increasing prosperity. Type 1 diabetes is also increasing, though less dramatically. Second, type 2 diabetes is responsive [...]
Contact:
